TSO3 Inc

TSO3 — Investor Presentation (July 2016)

23 slides from TSO3's investor presentation, July 2016

  1. Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing

    TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation July 2016

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing

  3. Slide 3: TSO3 - Our Vision

    TSO3 - Our Vision TSX:TOS To Create the Improved Standard in Healthcare Sterile Reprocessing™ 3

  4. Slide 4: Where We Are From and Where We Are Going

    Where We Are From and Where We Are Going TSX:TOS 2016 • Record revenue 2009 - 2014 • Reworked products • Record assembly capacity • Introduced STERIZONE® 125L+ • 91M shares oustanding1 and STERIZONE® VP4 Sterilizers • US$24.4M in cash2 • 18 sterilizers in operation at • Received flexible multi-chann

  5. Slide 5: Purpose

    Purpose TSX:TOS A Sterile Device for Every Procedure 5

  6. Slide 6: Approach

    Approach ity to Provide Sterile Sterilizer Devices to All Patients

  7. Slide 7: Modernizing Healthcare Sterilization Technology

    Modernizing Healthcare Sterilization Technology TSX:TOS Old Technology TSO3 Technology Low Temperature Sterilization Low Temperature Sterilization • 20+ year-old core technology  The next generation industry technology • Operators must choose from several operating cycles  Simple Single Cycle Oper

  8. Slide 8: Multiple Large Target Markets

    Multiple Large Target Markets TSX:TOS Existing Low-Temp Sterilizer Market NOW AVAILABLE: Endoscopy/GI Market • Fastest growing sterilization segment (9%–10% CAGR1) • Greenfield terminal sterilization opportunity for 75 million procedures annually in US & Europe by 20205 • Total equipment replacement

  9. Slide 9: STERIZONE VP4 Sterilizer

    STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error Proprietary Software automatically free cycle selection adjusts the steril

  10. Slide 10: The Science – Patents Pending or Applied For

    The Science – 36 Patents or Pending or Applied For TSX:TOS 10

  11. Slide 11: Key Market Driver: Demographics

    Key Market Driver: Demographics TSX:TOS  Aging population to result in Aging Population Expected to Drive increasing demand for minimally Growth in MIS Surgeries and Endoscopies invasive diagnostic and surgical procedures (MIS)1  Global population is aging  U.S. 65+ age group to grow 35%, from 40

  12. Slide 12: Endoscopy Market

    Endoscopy Market TSX:TOS “Despite reprocessing in accordance with US guidelines, viable  Many endoscopes, including microbes and biologic debris persisted in clinically used [GI] colonoscopes and gastroscopes endoscopes, suggesting current reprocessing guidelines are not are not terminally steriliz

  13. Slide 13: FDA Clearance of Extended Claims – an Industry First

    FDA Clearance of Extended Claims – an Industry First TSX:TOS FDA has cleared the STERIZONE® VP4  July 2016: FDA cleared expanded indications Sterilizer for the sterilization of multi- for use of STERIZONE® VP4 Sterilizer to include: channeled flexible endoscopes (with a maximum of four channels) ha

  14. Slide 14: Endoscopes & Superbugs

    Endoscopes & Superbugs TSX:TOS  SUPERBUG = Antimicrobial Resistant Bacteria  2 million+ Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1  CRE is resistant to most available antibiotics - up to 50% of infected patients die1  CRE infections increasingly prevalent and lin

  15. Slide 15: Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements

    Potential Future Regulatory Growth Driver: Evolution of Classification of Reprocessing Requirements TSX:TOS  Since multi-channeled flexible FDA Device Class endoscopes, including colonoscopes Highest Body Reprocessing and duodenoscopes are typically Contact Requirements Today Signaled not sterilize

  16. Slide 16: Getinge Infection Control Exclusive Global Distribution Agreement

    Getinge Infection Control Exclusive Global Distribution Agreement TSX:TOS “The STERIZONE® VP4 Sterilizer uniquely addresses an unmet global need for cost  Getinge - exclusive global distributor rights to effective, high throughput sterilization of STERIZONE® VP4 Sterilizer complex medical devices u

  17. Slide 17: Q1 2016 Financial Highlights – USD

    Q1 2016 Financial Highlights – USD TSX:TOS Quarterly Revenue  Q1 2016 Revenues a record $3.1M, primarily (US$ Millions) driven by 25 STERIZONE ® VP4 Sterilizers Shipped 25 STERIZONE® VP4 $3.1M shipped to Getinge Sterilizers to Getinge in the U.S.  Gross Margin of 36% - indicating equipment margins

  18. Slide 18: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All Dollars in USD, unless noted otherwise TSX:TOS Stock Price (7/14/16) CAD $3.30 Total Revenue (ttm) $4.3M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low CAD $1.42-$3.49 Gross Profit (ttm) $0.9M Avg. Daily Vol. (3 mo.) 0.3M High-margin consumables and Net Loss (ttm

  19. Slide 19: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TOS  STERIZONE® VP4 Sterilizer:  The ONLY FDA-cleared medical device sterilizer validated to terminally sterilize colonoscopes and gastroscopes Global Distribution Partner  Multiple breakthroughs in design, capability, effectiveness and operational cost to beat incumbent te

  20. Slide 20: Contact Us

    Contact Us TSX:TOS Investor Relations TSO3 Inc. - Canada Liolios Group, Inc. Ron Both, Senior Managing Director 2505, avenue Dalton Tel (949) 574-3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651-0003 Barry Mire, Vice President info@tso3.com Tel (

  21. Slide 21: Appendix

    Appendix + Bs

  22. Slide 22: Important Regulatory Growth Driver

    Important Regulatory Growth Driver TSX:TOS  FDA identified flexible endoscopes as known source of infection and cause of death  FDA has recorded 109 reports of infections or FDA safety communication: contamination related to bronchoscopes over the Design of endoscopic retrograde cholangio- pancrea

  23. Slide 23: Growth Strategies

    Growth Strategies TSX:TOS  Support Getinge for global introduction and Medical Reprocessing Lifecycle commercialization of STERIZONE® VP4 Sterilizer  Expand manufacturing/assembly operations  Broaden product portfolio:  Sterilizer products purpose-built for the operating room (OR)  Iterations o

TSO3 — Investor Presentation (July 2016) on 6ix